The problem with potency.
Scott
Christopher Thomas
CT
D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001327:Autoimmune Diseases / Q000276:immunology* / Q000628:therapy; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D007107:Immune System; D007167:Immunotherapy / Q000009:adverse effects / Q000191:economics / Q000379:methods*; D007249:Inflammation; D000069442:Natalizumab; D009369:Neoplasms / Q000628:therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D000069442:Natalizumab